Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Development of HIV vectors pseudotyped for lung gene therapy targets.
FY 2012-13
Summary
Cystic fibrosis (CF) is a genetic disease that affects most critically the lungs, but also the pancreas, the liver, and the intestine. It is the most common lethal inherited disease of Caucasian populations, affecting ~80,000 individuals worldwide with a median life expectancy of only ~36 years. Typically, CF individuals suffer from repeated bacterial infections of the airways eventually leading to respiratory failure. Current treatments are focused on providing symptomatic relief and fighting infections; for patients this is an important treatment burden, requiring several hours of self-administered therapy daily. To date, no treatment that targets directly the genetic defect is available, despite its identification in 1989. It is anticipated that correction of the genetic defect through gene therapy could be an effective therapy in the future. Although monthly administration of non-viral gene therapy is currently being investigated for Cystic Fibrosis in the clinical setting, it is anticipated that viral gene transfer might be more efficient and might persist longer. The project will therefore aim at producing a virus specifically adapted to enter airway cells to transfer the correct gene to these cells in affected patients. We hypothesise that this viral induced gene transfer into the airways will provide an effective treatment for Cystic Fibrosis' lung disease. There will also be an exciting opportunity to exploit these vectors as a delivery platform to treat other lung diseases in the future such as chronic obstructive pulmonary disease (COPD) and emphysema.
Department
Program
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Recipient
Location
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
283770
Name
Gélinas Jean-François
Country
United Kingdom
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development of HIV vectors pseudotyped for lung gene therapy targets.
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
Cystic Fibrosis; Gene Therapy; Lentiviral Vectors; Lung Diseases
Abstract
Cystic fibrosis (CF) is a genetic disease that affects most critically the lungs, but also the pancreas, the liver, and the intestine. It is the most common lethal inherited disease of Caucasian populations, affecting ~80,000 individuals worldwide with a median life expectancy of only ~36 years. Typically, CF individuals suffer from repeated bacterial infections of the airways eventually leading to respiratory failure. Current treatments are focused on providing symptomatic relief and fighting infections; for patients this is an important treatment burden, requiring several hours of self-administered therapy daily. To date, no treatment that targets directly the genetic defect is available, despite its identification in 1989. It is anticipated that correction of the genetic defect through gene therapy could be an effective therapy in the future. Although monthly administration of non-viral gene therapy is currently being investigated for Cystic Fibrosis in the clinical setting, it is anticipated that viral gene transfer might be more efficient and might persist longer. The project will therefore aim at producing a virus specifically adapted to enter airway cells to transfer the correct gene to these cells in affected patients. We hypothesise that this viral induced gene transfer into the airways will provide an effective treatment for Cystic Fibrosis' lung disease. There will also be an exciting opportunity to exploit these vectors as a delivery platform to treat other lung diseases in the future such as chronic obstructive pulmonary disease (COPD) and emphysema.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gélinas, Jean-François
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~